RE:Some thoughtsThanks for this valuable note, Proboscises.
In any negotiation, one has to think about what the bidders face as their alternatives to an agreement with your side. That is what should shape their reserve price or fallback position.
In this case, the science of the drug development and approval process is so complex and frought that they have very constrained (if not no) alternatives for what you offer. Also they are competing with their peers for your intelllectual property. Their future markets and corporate strategies depend on that every intellectual property.
I have always said we have the best bug for immunotherapy because of its specfic qualties, particularly ease of use and production. And now seems to finally be the time. All dependant, of course, on the coming specific news updates, and FDA responses.
I have been here only 10 years, and am also beyond glad.